Ax-8 is under clinical development by Axalbion and currently in Phase II for Chronic Cough. According to GlobalData, Phase II drugs for Chronic Cough does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ax-8 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ax-8 overview
Ax-8 is under development for the treatment of chronic cough.The therapeutic candidate is administered by oromucosal, and topical route. It targets transient receptor potential cation channel subfamily M member 8 (TRPM8). The drug candidate is developed based on TRPM8 technology.
It was also under development for the treatment of inflammatory bowel disease, pruritus, and NERD(non-erosive reflux disease).
For a complete picture of Ax-8’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.